Alpha防御素侧流试验诊断假体周围关节感染的验证
本研究为诊断准确性研究,纳入前瞻性多中心队列的57例假体周围关节感染(PJI)患者和248例非PJI患者,评估滑液Alpha防御素侧流试验的诊断性能,并与实验室Alpha防御素试验比较。侧流试验敏感度89.5%、特异度94.8%;排除17例肉眼血性穿刺液后敏感度升至94.3%。补充对照组中敏感度98.5%、特异度98.2%。侧流试验与酶联免疫吸附试验(ELISA)在敏感度和特异度上无显著差异(均p>0.05)。
要点
- 在前瞻性多中心队列中,Alpha防御素侧流试验诊断PJI的敏感度为89.5%、特异度为94.8%。
- 排除17例肉眼血性穿刺液(红细胞>100万/µL)后,敏感度升至94.3%。
- 侧流试验与ELISA在敏感度和特异度上无显著差异(均p>0.05)。
核心结论
- 研究结果表明Alpha防御素试验具有可靠的诊断性能,并促成了美国食品药品监督管理局(FDA)授权该侧流试验作为PJI临床诊断的辅助手段。
研究设计与样本
- 诊断准确性研究,以前瞻性多中心队列的门诊髋或膝关节置换失败患者为研究对象,并补充医生送检的新鲜滑液标本作为对照组。
- 参考标准为2013年肌肉骨骼感染学会(MSIS)多标准PJI定义。
- 证据等级为诊断II级。
主要发现
- 在总体前瞻性患者队列中(57例PJI、248例非PJI),Alpha防御素侧流试验的敏感度为89.5%(95%CI:78.5%至96.0%),特异度为94.8%(95%CI:91.2%至97.2%)。
- 排除17例肉眼血性穿刺液(红细胞>100万/µL)后,敏感度升至94.3%(95%CI:84.3%至98.8%)。
- 在补充对照队列的新鲜滑液样本中(65例PJI、397例非PJI),侧流试验的敏感度为98.5%(95%CI:91.7%至100.0%),特异度为98.2%(95%CI:96.4%至99.3%)。
- 在合并队列中,侧流试验与Alpha防御素酶联免疫吸附试验(ELISA)的敏感度分别为94.3%(95%CI:88.5%至97.7%)和93.0%(95%CI:87.1%至96.7%),特异度分别为96.9%(95%CI:95.3%至98.1%)和97.8%(95%CI:96.4%至98.8%),差异均无统计学意义(均p>0.05)。
关键数值与推荐
- PJI参考标准为2013年MSIS多标准定义。
- 肉眼血性穿刺液定义为红细胞>100万/µL。
临床怎么用
- 美国食品药品监督管理局(FDA)授权该侧流试验作为PJI临床诊断的辅助手段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The synovial fluid test for alpha defensin has been reported to have an excellent performance in diagnosing periprosthetic joint infection (PJI). The purpose of this study was to evaluate the performance of the lateral flow test for synovial fluid alpha defensin by using the methods of a formal diagnostic accuracy study and to compare its performance with that of the laboratory-based alpha defensin test for PJI. METHODS: We conducted a diagnostic accuracy study of the index lateral flow immunoassay for synovial fluid alpha defensin relative to the reference 2013 Musculoskeletal Infection Society (MSIS) multicriteria definition of PJI. The study included a prospective multicenter cohort of outpatients with a failed hip or knee arthroplasty and a supplemental control cohort of fresh synovial fluid specimens submitted by physicians for diagnostic PJI testing. RESULTS: Among 57 patients with PJI and 248 patients without PJI in the overall prospective patient cohort, the sensitivity and specificity of the alpha defensin lateral flow test were 89.5% (95% confidence interval [CI]: 78.5% to 96.0%) and 94.8% (95% CI: 91.2% to 97.2%), respectively. The sensitivity increased to 94.3% (95% CI: 84.3% to 98.8%) after exclusion of 17 patients with grossly bloody aspirates (>1 million red blood cells/µL). Among the supplemental control cohort of fresh synovial fluid samples, including 65 samples from patients with PJI and 397 from patients without PJI, the sensitivity and specificity of the alpha defensin lateral flow test were 98.5% (95% CI: 91.7% to 100.0%) and 98.2% (95% CI: 96.4% to 99.3%), respectively. A comparison of the sensitivity and specificity of the alpha defensin lateral flow test with those of the alpha defensin enzyme-linked immunosorbent assay (ELISA) in the combined cohort did not demonstrate a significant difference in sensitivity (94.3% [95% CI: 88.5% to 97.7%] compared with 93.0% [95% CI: 87.1% to 96.7%]) or specificity (96.9% [95% CI: 95.3% to 98.1%] compared with 97.8% [95% CI: 96.4% to 98.8%]) (both p > 0.05). CONCLUSIONS: The results of this study demonstrate the solid diagnostic performance of the alpha defensin test and have resulted in the U.S. Food and Drug Administration (FDA) authorization of the lateral-flow test with an intended use as an aid in the clinical diagnosis of PJI. LEVEL OF EVIDENCE: Diagnostic Level II. See Instructions for Authors for a complete description of levels of evidence.
引用
- Deirmengian C, Madigan J, Kallur Mallikarjuna S, et al. Validation of the Alpha Defensin Lateral Flow Test for Periprosthetic Joint Infection. J Bone Joint Surg Am. 2021. PMID: 33165130. doi:10.2106/JBJS.20.00749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。